Evidence map›Paper›PMID 22130905›Full record

Trial reportSchizophrenia bulletin2013

A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up.

John F M Gleeson, Sue M Cotton, Mario Alvarez-Jimenez, Darryl Wade, Donna Gee, Kingsley Crisp, Tracey Pearce, Daniela Spiliotacopoulos, Belinda Newman, Patrick D McGorry

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia bulletin, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 6 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 6 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Training to recognise the early signs of recurrence in schizophrenia.The Cochrane database of systematic reviews · 2013
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Article
  15. The "online brain": how the Internet may be changing our cognition.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2019
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

John F M GleesonSchool of Psychology, Australian Catholic University, Level 2, 115 Victoria Parade Fitzroy, VIC 3065, Australia. john.gleeson@acu.edu.au
Sue M Cotton
Mario Alvarez-Jimenez
Darryl Wade
Donna Gee
Kingsley Crisp
Tracey Pearce
Daniela Spiliotacopoulos
Belinda Newman
Patrick D McGorry
Orygen Youth Health · AUAustralian Catholic University · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effectiveness of a novel 7-month psychosocial treatment designed to prevent the second episode of psychosis was evaluated in a randomized controlled trial at 2 specialist first-episode psychosis (FEP) programs. An individual and family cognitive behavior therapy for relapse prevention was compared with specialist FEP care. Forty-one FEP patients were randomized to the relapse prevention therapy (RPT) and 40 to specialist FEP care. Participants were assessed on an array of measures at baseline, 7- (end of therapy), 12-, 18-, 24-, and 30-month follow-up. At 12-month follow-up, the relapse rate was significantly lower in the therapy condition compared with specialized treatment alone (P = .039), and time to relapse was significantly delayed for those in the relapse therapy condition (P = .038); however, such differences were not maintained. Unexpectedly, psychosocial functioning deteriorated over time in the experimental but not in the control group; these differences were no longer statistically significant when between-group differences in medication adherence were included in the model. Further research is required to ascertain if the initial treatment effect of the RPT can be sustained. Further research is needed to investigate if medication adherence contributes to negative outcomes in functioning in FEP patients who have reached remission, or, alternatively, if a component of RPT is detrimental.

Indexed as

AdolescentAdultAntipsychotic AgentsCognitive Behavioral TherapyCombined Modality TherapyDelivery of Health CareFamily TherapyFemaleFollow-Up StudiesHumansMaleMedication AdherencePsychotic DisordersSecondary PreventionTreatment OutcomeYoung AdultAntipsychotic Agents

Identifiers

PMID22130905
PMCPMC3576162
OpenAlexW2149232553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.